Immunogenicity and protection in small-animal models with controlled- release tetanus toxoid microparticles as a single-dose vaccine

Infection and Immunity

Volumn 65, Issue 5, 1997, Pages 1716-1721

  Singh, Manmohan ^a,c   Li, Xuan Mao ^a   Wang, Hanying ^a   McGee, J P ^b   Zamb, Tim ^a   Koff, Wayne ^a   Wang, Chang Yi ^a   O'Hagan, D T ^a,c  

^a United Biomedical Inc   (United States)

^b HANNAH RESEARCH INSTITUTE   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TETANUS TOXOID;

ANIMAL MODEL; ARTICLE; CLOSTRIDIUM TETANI; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TETANUS;

EID: 0030952306     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.5.1716-1721.1997     Document Type: Article

References (37)

1. Aguado, M. T. 1983. Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems. Vaccine 11:596.
2. Aguado, M. T., and P. H. Lambert. 1992. Controlled release vaccines - biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. Immunobiology 184:113-125.
3. Almeida, A. J., H. O. Alpar, and M. R. W. Brown. 1993. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea pigs. J. Pharm. Pharmacol. 45:198.
4. Alonso, M. J., R. K. Gupta, M. Caroline, G. R. Siber, and R. Langer. 1994. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 12:299.
5. Anderson, E. L., M. M. Chrisanna, B. S. Berlin, C. N. Shin, F. F. Tung, and R. B. Belshe. 1994. A cellular pertussis vaccines in infants: evaluation of single component and two-component products. Vaccine 12:28-31.
6. Burns, R. A., J. Vitale, and L. M. Sanders. 1990. Nafarelin controlled release injectable: theoretical clinical plasma profiles from multiple dosing and from mixtures of microspheres containing two per cent, four per cent and seven per cent Nafarelin. J. Microencapsulation 7:397-413.
7. Chandrasekaran, R., D. K. Giri, and M. R. Chaudhury. 1996. Embryotoxicity and teratogenicity studies of poly (DL-lactide-co-glycolide) microspheres incorporated tetanus toxoid in wistar rats. Hum. Exp. Toxicol. 15:349-351.
8. Chaudhury, M. R., K. Sharma, and D. K. Giri. 1996. Poly (D,L-lactide) glycolidc polymer microsphere entrapped tetanus toxoid: safety evaluation in wistar rats. Hum. Exp. Toxicol. 15:205-207.
9. Clemens, J. D., C. Ferriccio, M. M. Levine, I. Horwitz, M. R. Rao, K. M. Edward, and B. Fritzell. 1992. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on response to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA 267:673-678.
10. Cutwright, D. E., E. Perez, J. D. Beasley, W. G. Larson, and W. R. Posey. 1974. Degradation of poly (lactic acid) polymer and co-polymers of poly (glycolic acid). J. Oral Surg. 37:132-142.
11. Eldridge, J. H., J. K. Stass, J. A. Meulbroek, J. R. McGhee, T. R. Tice, and R. M. Gilley. 1991. Biodegradable microspheres as a vaccine delivery system. Mol. Immunol. 28:287.
12. Ferreccio, C., J. Clemens, A. Avendano, I. Horwitz, C. Flores, and L. Avila. 1991. The clinical and immunologic response of children and infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine co-administered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J. 10:764-771.
13. Furr, B. J. A. 1987. Pharmacological studies with Zoladex, a novel luteinizing hormone-releasing hormone analogue. R. Soc. Med. Int. Congr. Symp. Ser. 125:1.
14. Glenny, A. T., and B. E. Hopkins. 1923. Diphtheria toxoid as an immunizing agent. Br. J. Exp. Pathol. 4:283.
15. Gupta, R. K., S. C. Maheswari, and H. Singh. 1985. The titration of tetanus antitoxin. IV. Studies on the sensitivity and reproducibility of the toxin neutralization test. J. Biol. Stand. 13:143-149.
16. Hutchinson, F. G., and B. J. A. Furr. 1986. Biodegradable polymers in sustained release of polypeptides, p. 115-124. In S. S. Davis, L. Illum, and E. Tomlinson (ed.), Delivery systems for peptide drugs. Plenum, New York, N.Y.
17. Jeffery, H., S. S. Davis, and D. T. O'Hagan. 1991. The preparation and characterisation of poly(lactide-co-glycolide) microparticles. I. Oil-in-water emulsion solvent evaporation. Int. J. Pharm. 77:169-177.
18. Jeffery, H., S. S. Davis, and D. T. O'Hagan. 1993. The preparation and characterization of poly(lactide-co-glycolide) microparticles. 11. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharmacol. Res. 10:362.
19. Lee, J. W. 1995. Search for one-dose tetanus vaccine approaches first dead-line. Children's Vaccine Initiative Forum 10:17-18.
20. McGee, J. P., M. Singh, X. M. Li, H. Qiu, and D. T. O'Hagan. 1997. The encapsulation of a model protein in poly (D,L lactide-co-glycolide) microparticles of various sizes - an evaluation of process reproducibility. J. Microencapsulation 14:197-210.
21. Men, Y., C. Thomasin, H. P. Merkle, B. Gander, and G. Corradin. 1995. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 13:683.
22. National Institutes of Health. 1952. Minimum requirements for tetanus toxoid, 4th ed. National Institutes of Health, Bethesda, Md.
23. O'Hagan, D. T. 1990. Intestinal translocation of particulates - implications for drug and antigen delivery. Adv. Drug Delivery Rev. 5:265-285.
24. O'Hagan, D. T., H. Jeffery, M. J. J. Roberts, J. P. McGee, and S. S. Davis. 1991. Controlled release microparticles for vaccine development. Vaccine 9:768-771.
25. O'Hagan, D. T., D. Rahman, J. P. McGee, H. Jeffery, M. C. Davies, P. Williams, and S. S. Davis. 1991. Biodegradable microparticles as controlled release antigen delivery system. Immunology 73:239.
26. Pitt, C. G., M. M. Gratzl, G. L. Kummel, J. Surles, and A. Schindler. 1981. Aliphatic polyesters II. The degradation of poly (DL-lactide) and their copolymers in vivo. Biomaterials 2:215.
27. Ramon, G. 1924. Sur la toxine et surranatoxine. Ann. Inst. Pasteur (Paris) 38:1.
28. Rappuoli, R., A. Podda, F. Giovannoni, L. Nencioni, M. Peragallo, and P. Francolini. 1993. Absence of protective immunity against diphtheria in a large proportion of young adults. Vaccine 11:576-577.
29. Schwandeman, S. P., H. R. Costantino, R. K. Gupta, G. R. Siber, and R. Langer. 1995. Mechanisms of moisture-induced aggregation of tetanus toxoid. Proc. Int. Symp. Cont. Rel. Bioact. Mater. 22:41-42.
30. Schwendeman, S. P., H. P. Costantino, R. K. Gupta, G. R. Siber, A. M. Kibanov, and R. Langer. 1995. Stabilization of tetanus and diphtheria tox oids against moisture induced aggregation. Proc. Natl. Acad. Sci. USA 92: 11234
31. Shepard, D. S., J. A. Walsh, E. Kleinav, S. Stansfield, and S. Bhalotra. 1995. Setting priorities for the children's vaccine initiative: a cost effectiveness approach. Vaccine 13:707-714.
32. Singh, M., O. Singh, and G. P. Talwar. 1995. Biodegradable delivery system for a birth control vaccine: immunogenicity studies in rats and monkeys. Pharmacol. Res. 12:1796.
33. Singh, M., L. Xuan-Mao, J. P. McGee, T. Zamb, W. Koff, C. Y. Wang, and D. T. O'Hagan. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine, in press.
34. Tabata, Y., and Y. Ikada. 1988. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophages. Biomaterials 9:356-362.
35. Tice, T. R., D. W. Mason, and R. M. Gilley. 1989. Clinical use and future of parenteral microsphere delivery systems, chapter 21. In F. Prescott and W. S. Nimmo (ed.), Novel drug delivery and its therapeutic applications. John Wiley & Sons, London, United Kingdom.
36. Wise, D. L., T. D. Fellman, J. E. Sanderson, and R. L. Wentworth. 1979. Lactide/glycolide polymers used in as surgical suture material, raw material for osteosynthesis and in sustained release forms of drugs, p. 237. In G. Gregoriadis (ed.), Drug carriers in medicine. Academic Press, London, United Kingdom.
37. Yamaguchi, K., and J. M. Anderson. 1993. In vivo biocompatibility studies of medisorb 65/35 D,L-lactide/glycolide copolymer microspheres. J. Controlled Release 24:81.